Three significant de novo classifications from the past several years were made official this week by US FDA. The agency issued orders designating high-throughput next-generation sequencing analyzers, "secondary displays" for continuous glucose meters, and vibratory counter-stimulation devices into class II with special controls.
FDA handed down the positive de novo decisions in 2013 and 2015, but the March 14 orders formally record the new class II device types and the marketing standards for future devices in the same categories
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?